Provided by Tiger Trade Technology Pte. Ltd.

SAB Biotherapeutics, Inc.

2.98
-0.0800-2.61%
Post-market: 3.000.0200+0.67%19:30 EDT
Volume:416.32K
Turnover:1.25M
Market Cap:271.14M
PE:-1.91
High:3.12
Open:3.10
Low:2.96
Close:3.06
52wk High:5.15
52wk Low:1.97
Shares:90.99M
Float Shares:62.04M
Volume Ratio:0.41
T/O Rate:0.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5562
EPS(LYR):-0.7944
ROE:-11.27%
ROA:-33.46%
PB:1.26
PE(LYR):-3.75

Loading ...

SAB Biotherapeutics Presents Phase 1 Data for SAB-142 Immunotherapy in Stage 3 Type 1 Diabetes at CRC 2026

Reuters
·
Oct 01

Press Release: SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes

Dow Jones
·
Sep 22

SAB Biotherapeutics CEO Samuel Reich Joins Citi Biopharma Back to School Conference Fireside Chat

Reuters
·
Sep 01

SAB Biotherapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

SAB Biotherapeutics Q2 FY26 Net Loss Widens to $22.5 Million; R&D Expenses More than Doubled to $16.2 Million

Reuters
·
Aug 06

SAB Biotherapeutics Q2 2026, Cash Balance Of $208.0M, Providing Runway Through 2028

Benzinga Earnings
·
Aug 06

Press Release: SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights

Dow Jones
·
Aug 06

SAB Biotherapeutics Inc Expected to Post a Loss of 29 Cents a Share - Earnings Preview

Reuters
·
Aug 04

SAB Biotherapeutics Schedules Q2 2026 Earnings Call and Webcast

Reuters
·
Jul 30

Breakthrough T1d Awards Grant to Support Prise‑hatg Study of Sab‑142 in Stage 3 Type 1 Diabetes

THOMSON REUTERS
·
Jul 07

Breakthrough T1D Awards Grant to Support Uf-led Prise-hatg Study of SAB Bio’s Sab-142 in Stage 3 Type 1 Diabetes

Reuters
·
Jul 07

U.S. Research Roundup-caseys General Stores, Micron Technology, SAP

Reuters
·
Jun 25

SAB Biotherapeutics Initiated at Overweight by Barclays

Dow Jones
·
Jun 25

Barclays Initiates SAB Biotherapeutics at Overweight With $13 Price Target

MT Newswires Live
·
Jun 24

SAB Biotherapeutics shareholders elect four Class II directors at annual meeting

Reuters
·
Jun 19

SAB Biotherapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
Jun 17

Chardan Adjusts Price Target on SAB Biotherapeutics to $16 From $14, Maintains Buy Rating

MT Newswires Live
·
Jun 17

Analysts Are Bullish on Top Healthcare Stocks: Ryman Healthcare (RHCGF), SAB Biotherapeutics (SABS)

TIPRANKS
·
Jun 17

Craig-Hallum Remains a Buy on SAB Biotherapeutics (SABS)

TIPRANKS
·
Jun 16

SAB Biotherapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 15